15 per share, recognized in the third quarter as an impairment charge related to Amphotec
is cleared for marketing in Argentina for treatment of severe systemic and/or deep mycoses in patients for whom conventional amphotericin B therapy cannot be used in effective doses due to toxicity or impaired renal function, or in patients who have failed conventional systemic antifungal therapy.
8 million for the impairment of Amphotec
A total of 149 patients with blood cultures positive for Candida were treated with AMPHOTEC
during a course of five clinical trials.
SEQUUS is developing AMPHOTEC
for the treatment of life-threatening systemic fungal infections such as aspergillosis, candidiasis and cryptococcal meningitis in patients who have failed other therapy or are intolerant to amphotericin B.
By aligning ourselves with a regional company, we believe that we can accelerate the market acceptance of AMPHOTEC
and capitalize on the growing interest in new anti-fungal therapy.
Three Rivers Pharmaceuticals is very pleased to be acquiring Amphotec
from InterMune," stated Donald J.
We are pleased that the FDA has agreed to include this additional information in the AMPHOTEC
label," said Dr.
Combined revenues from sales of DOXIL and AMPHOTEC
were below analysts' expectations.
Diseases demonstrate that, as compared to amphotericin B, AMPHOTEC
The increase in cost of goods sold as a percentage of total revenue was primarily the result of a shift in the product mix towards a higher proportion of revenue from Infergen, which has a lower profit margin than Actimmune, and an inventory write-off associated with the divestiture of Amphotec
during the quarter.
The results of this study show that AMPHOTEC
was significantly more effective than either amphotericin B or Abelcet and that AmBisome was approximately equivalent to AMPHOTEC